Dr. Thomas Herzog on Who Benefits From Neoadjuvant Therapies
Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.
Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.
Herzog says, in most cases, depending on the patient’s health, primary cytoreduction would be the ideal way to go for treatment. While he considers neoadjuvant therapies to be a standard of care, he does not consider them to be the standard of care.
First-in-Class Drug AMG 193 Exploits Tumor Weakness for Targeted Therapy
September 17th 2024In a first-in-human trial, AMG 193, a drug targeting a specific mutation in tumors, showed promising results in reducing tumor size and spread in various cancers, with an acceptable safety profile.
Read More
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
